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ABSTRACT 
Parkinson's disease (PD) is a common progressive neurological 
disorder. It affects the central nervous system by depleting the basal ganglia 
of dopamine. To date, the standard treatment is drug therapy to replace the 
lacking dopamine. However, this treatment is problematic as there are many 
side effects to the drugs. Also, this treatment does not effect the progression 
of this disease. Therefore, drug therapy becomes continuously less effective 
in treating PD. For this reason, new fonns of therapy are being researched 
for the treatment of advanced PD. One of the most recent therapeutic 
interventions is fetal tissue transplantation. 
The purpose of the independent study is to review literahlre regarding 
fetal tissue transplantation in PD. This study will include a brief overview of 
the pathophysiology and current treatment methods for PD. Also, an 
overview of the history of neural transplantation for PD will be presented. In 
addition, the paper will include a discussion of the ethical and legal issues 
surrounding fetal tissue transplantation. 
Physical therapists CPT) treat many patients with PD. In the future, 
PT's maybe responsible for rehabilitating PD patients following fetal tissue 
transplantation surgery. This paper may be used as a tool by PT's to gain a 
greater understanding of a very innovative research technique. 
CHAPTER 1 
PD PATHOLOGY AND TREATMENT 
In 1917 , James Parkinson published an essay about the shaking palsy. 1,2 
This disorder was subsequently named Parkinson's disease (PD). PD is a 
debilitating neuro-muscular disease which presents with numerous 
pathological movement symptoms. The disease affects the motor planning 
areas of the brain. The primary manifistations are rigidity, bradykinesia, and 
tremor.2,3 PD causes an inability to initiate movements as well as a 
characteristic "pill-roll" involuntarily tremor.2-4 PD also presents with flexed 
posture, festinating gait and "cog-wheel" or "lead-pipe" rigidity. 3, 4 The 
rigidity is different than that displayed in spasticity because there is an 
increase in antagonist as well as agonist neuromuscular output. 3 PD also 
decreases associated movements such as : normal ann swing during gait, 
facial expressions, and gestures during conversation.2,3 
The anatomical structures involved in PD include the basal ganglia and 
the substantia nigra. The term basal ganglia is used to designate several 
structures including the caudate nucleus, putamen, and globus pallidus. 3,4 
These structures are intimately related to the cerebral cortex, thalamus, and 
substantia nigra through networks of neurons. 4 The structures of the basal 
ganglia are thought to be involved in the planning and programming of 
voluntary movements.3 
PD is referred to as the most common type of basal ganglia disease.2,4 
Patho-physiology of the disease is characterized by massive degeneration of 
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the substantia nigra. 4 There is also a depletion of dopamine, an inhibitory 
neurotransmitter of the caudate nucleus and putamen. 4 This is caused by a 
degeneration of the neurons of the basal gang1ia. I-4 This is a process of 
nonnal aging, however in PD, this steady loss of dopamine is acce1erated.3 
Dopamine levels in persons with PD may be as low as 50% of normal. 3 
With the degeneration of the basal ganglia and subsequent loss of 
dopaminergic cells, the usual balance between excitatory acetylocholine and 
inhibitory dopamine is disrupted. This imbalance leads to an impairment of 
the control of smooth, voluntary movement. I 
To date, the principle treatment for PD has been drug therapy to replace 
the lacking dopamine. However, this has been problematic as dopamine 
cannot cross the blood brain barrier (BBB). Dopamine is therefore 
prescribed in the fonn of leva dopa (L-dopa), which will penetrate the BBB.I-
3 L-dopa is the metabolic precursor of dopamine.2. 3 L-dopa is combined 
with a dopa-inhibitor (Sinamet or Madopar) to prevent it from being 
converted to dopamine in the periphery.I-3 
Treatment of PD with drug therapy has many undesirable side-effects. 
These include nausea, vomiting, hallucinations, dizziness, and painful 
spasms or cramps.l.2 There is also the development of the lion-off' 
phenomenon or end-of-dose deterioration. This is a fluctuation in 
performance and drug response.2 Fietcher l describes the on-off phenomenon 
as periods of abnormal mobility, alternating with periods of complete 
immobility. According to O'Sullivan 2, 50% of patients taking L-dopa for 
more than two years experience the on-off phenomenon. 
L-dopa therapy does not influence disease progression.l.2 \Vith the 
advancement of the disease, drug therapy is less effective as the number of 
dopamine producing cell decreases. I. 2 To continue to get the therapeutic 
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effects of L-dopa, increasingly larger doses are required. l In time, patients 
develop adverse side effects or become tolerant of the drug. S Patients with 
decreased responsiveness to L-dopa may be put on "drug holiday".2.6 This is 
a period of 7-10 days of transient withdrawal from the drug. 2 This may 
enhance motor response to L-dopa and decrease the negative effects of the 
drug. 
Because the treatment of severe PD is so problematic, new forms of 
therapy are being researched. One of the most innovative and often 
controversial is neural transplantation, which will be discussed in chapter 2. 
CHAPTER 2 
HISTORY OF NEURAL TRANSPLANTATION 
Neural transplantation, first perfonned in 1890, was initially perceived as 
an experimental tool for the systematic study of neural development and 
regeneration.7,8 In contemporary science, neural transplantation is rapidly 
becoming a potential treatment for some previously difficult diseases, 
namely PD. Research on neural transplantation with respect to PD began 
with extensive work utilizing animal models. This approach was then 
adopted in human patients in 1985. According to Rosenfeld et a1,7 "Since 
that time several hundred human transplants have been carried out for PD 
with only limited success". 
Two very different basic procedures have been done with neural 
transplantation for severe PD. One method is to take dopamine 
manufacturing cells from the adrenal medulla and place them directly into 
the substantia nigra of that same individual. Bakay and Barrow 9 reviewed 
eleven reports and found that this procedure has been perfonned 84 times 
since 1985 with a 33 % incidence of major complications. This may be due 
to the fact that three major procedures must be performed consecutively, 
with as little time lapse as 10-12 hours. First, the tissue must be excised 
from the adrenal medulla of the patient. Secondly, that tissue must be made 
into a suspension. Finally, the tissue is then implanted into the substantia 
nigra of the patient. Regarding adrenal medulla transplant, according to 
Rosenfeld et al, 7 it has been found that "some patients have apparently 
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improved significantly in the short tenn but this has not been sustained", 
Further discussion of adrenal medullary grafts is beyond the focus of this 
paper. 
"Following the overall failure of adrenal medullary grafts, attention 
swung toward the use of fetal tissue to replace damaged or lost neurons in 
PD" ,8 With fetal tissue transplant, tissue from the mesencephalon of aborted 
fetuses is made into a suspension and injected, through a frontal burr hole, 
into the basal ganglia of a PD patient. The origin of the fetal tissue (from 
voluntary abortions) is the cause of much ethical debate, 
Collectively, the findings of the literature reviewed are contradictory, 
Both inter and intra study results are inconsistent. Most patients showed 
improvements which were of scientific relevance, however, because their 
quality of life was not noticably changed, these patients did not view the 
procedure as a success,8 The procedures and results of seven studies of 
experimental fetal neural transplantation surgeries for PD will be reviewed 
and discussed in the following chapter. 
CHAPTER 3 
FTT STUDIES REVIEWED 
A Czechoslovakian experiment by Subrt et al 8 was published in 1991. In 
this study, three patients with PD who received neural transplantation were 
followed for one year. The patients were closely monitored for two months 
prior to surgery. The surgery technique included transplantation of 
mesencephalic tissue from 7-8 week old fetuses into three advanced PD 
patients. A frontal burr hole was used to implant the tissue stereo-
graphically into the head of the caudate nucleus of the three patients. A 
longer outer cannula was used to prepare the bed for the transplant. Then 
fetal tissue was placed with a small inner cannula. 
The three patients had immediate prolongation of On phase. 8 Other 
improvements became apparent at approximately three months. Patients 
became relieved of L-dopa side effects and doses were reduced. One patient 
showed remarkable results. Before the procedure, she was bed-ridden and 
symptoms could only be alleviated by intravenous anticholinergic drugs. 
After surgery, she could eat alone and ambulate with a cane. The other two 
patients L-dopa levels were reduced to 60% the pre-surgery dosage. 
However, these two patients did not value their improvements as their 
lifestyles did not change. 
The research team has already begun to modify its procedure as other 
studies are done. They anticipate that transplantation \vill be a viable 
alternative to drug therapy. 
6 
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In a study by Henderson et al,lo 12 patients received Fetal Transplant 
Tissue for advanced PD. Of the 12, nine patients were consistently followed 
for 12 months post-operatively. All patients were at Hoehn-Yahr II stage 4/5 
(Table 1.) before surgery. The procedure was an injection of Fetal Tissue 
through a right frontal burr hole into the caudate nucleus of each patient. 
Twelve patients had surgery, three of which did not comply with the 
follow-up schedule. Of the nine monitored for 12 months post-operative, 
four" experienced immediate subj ective post-operative improvements" .10 
Five patients had a mean decrease in levadopa dosage of 60% of their 
previous levels at 12 months. One patient did not need levadopa treatment 
at 12 months and another individual required only 10% of pre surgery 
dosage. At one year, three patients deteriorated compared to pre-operative 
assessment. Maximal changes were seen at six months after surgery. These 
researchers concluded that there are many operations being done world-wide 
and research will continue at the same rate as the "increasing understanding 
of human fetal development and the patho genesis of PD" .10 
In a study by Freed et al,6 seven patients who had advanced PD for 7-20 
years received FTT. Patients ranged in age from 39-66 years old. 
Preoperatively, five patients were rated a stage IV on the Hoehn-Yahr scale 
and two patients were rated stage III. For all patients selected, dmg therapy 
had failed and most were experiencing significant on-off phenomenon. This 
included periods of complete immobility, falling and dyskinesia. Patients 
were evaluated daily for four months to one year pre-surgery and 12-46 
months post-surgery. 
Fetal tissue, six to eight weeks old, was injected stereotaxically into as 
many as nine needle tracts.6 This study focused on the putamen as the 
transplant site. Patient one and two received grafts to the caudate and 
Stage I 
Stage II 
Stage III 
Stage IV 
Stage V 
8 
Minimal unilateral Disbility 
Minimal disability either bilateral or midline 
Righting reflexes are impaired, patient 
lives independently with some restrictions 
in activities 
Parkinson's manifestations are present and severe 
Patient is either bed or wheelchair bound 
Table 1. Hoehn and Yahr PD Rating Scale 11 
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putamen unilaterally. Patients three through seven had bilateral grafts to the 
putamen only. 
Overall, the group dropped an average of l.2 stages on the Hoehn-Yahr 
scale with the greatest difference from a stage IV to a stage II post-
operative.6 The level of dopamine dosage dropped an average of 39% for 
the seven patients. The largest decrease in dosage was 58%. Patient one, at 
46 months, showed the greatest improvements in the contralateral hand. His 
time spent in "on" phase went from 70 to 85 % of his day. Patient two 
showed no clinical improvement over a 33 month examination period. 
Patient three, at 21 months, had a reduction in periods of dyskinesia, as well 
as, time spent in the "off' phase. This patient appeared normal at times and 
had resumed social activities. Patient four had been followed for 13 months. 
She regained control of her gait and did not fall as she had pre-operatively. 
She was in the "on" phase 100% of the day, as compared to 65% of the day 
before surgery. Patient five had, before surgery, experienced extreme on-off 
phenomenon. At 12 months, the patient had a considerable reduction in 
duration and severity of "off' phase and dyskinesia following surgery. This 
patient was able to regain his driver's license. Patient six, at 12 months after 
surgery, returned to his pre-operative level of function with improved 
postural control and a marked decrease in bradykinesia. At 11 n10nths 
following surgery, patient seven had normal movement for as much as 30% 
of the day. Prior to surgery, he had no movement classified as nOlmal. This 
patient went from sleeping only three hours per night before FTT to eight 
hours after. 
These authors stated that all patients in this study, made improvements in 
the "On" phase.6 Four of the patients, and their physicians, felt the gains 
significantly changed their daily lives. These researchers contended that a 
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placebo effect may be ruled out on the grounds that adrenal medullary graft 
patients did not sustain their improvements. The authors concluded that FTT 
may add a new dimension to the treatment of severe PD. 
In a study by Spencer et al,12 four patients received FTT. The implants 
were injected stereotaxically into the right caudate nucleus. The patients 
needed three or four of the cardinal signs ofPD to be included in the study. 
These signs were resting tremor, rigidity, bradykinesia and postural 
instability. Also, the individual had to be at a Hoehr-Yahr stage IV. 
The results of the study are discussed in the following paragraphs. 
Patient one, pre-operatively, was house bound and unable to perfonn 
activities of daily living.12 After surgery, she had gradual reduction in 
bradykinesia, and rigidity, and improvements in gait ability. She also had 
improvements in visual searching, visual memOlY, and cognitive testing. 
However, after six months, all measures retunled to pre-operative baselines 
with the exception of visual searching. Patient two was very involved pre-
operatively. Following surgery, he showed minimal gains in autonomic 
functions. This patient died four months after receiving FTT. Post-mortum 
examination documented that the FTT grafts showed a viable blood supply 
and the formation of synaping neurons. Patient three presented with resting 
tremor, rigidity, gait disorder and dysphasia before surgery. Following FTT, 
this patient developed motor seizures, transient panic disorder, agoraphobia, 
and major depression. These were all controlled with medications. The 
patient had an increase in IQ test score of 14 points. Patient four was 
significantly debilitated by the on-off phenomenon before receiving FTT. 
He was unable to perform activities of daily living. Post-surgery, his trend 
towards worsening rigidity and tremor stabilized. A one year follow-up 
study showed an increase of nine points in his IQ. 
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Overall, the most significant result was that patients· levadopa leve Is 
decreased by 60%. The grafts were placed unilaterally in all patients, 
however, there was no change in function between the two sides of the body. 
The authors concluded that moderate bilaterally improvements were made in 
specific motor tasks. However, the patients still remained markedly affected 
by their disease according to the Hoehn-Yahr scale. These authors 
concluded that it is difficult to compare FTT studies as research teams use 
different procedures and evaluation methods. In addition, the procedure of 
FTT IIremains highly investigational and should not yet be considered a 
clinical treatment for PD. 1112 
In an on-going study by Lindvall et al,13 a total of four patients have 
received FTT for PD. A recently published article described the results of 
one-year clinical observations of two of those patients (patients three and 
four). The patients entered the study one year before surgery and were 
followed for one year post-operatively. Patients self-monitored their n10tor 
symptoms in a daily log every 30 minutes. The patients were also evaluated 
every two weeks by the researchers for an eight hour period. 
The procedure was stereotaxic implantation of ventral mesencephalic 
tissue in the anterior, mid and post putamen on the side contralateral to the 
most involved limb. 13 Patient three was a 50 year old male with stage III 
Hoehn-Yahr PD pre-operative. During off periods he had severe rigidity, 
moderate tremor, and hypokinesia immediately following FTT. Patient three 
had an increase in PD symptoms followed by a significant decrease in time 
spent in off phase. According to the patient, there was a decrease in rigidity. 
However, the patient had a slight increase in muscle tone. 
Patient four was a 60 year old male with stage III Hoehn-Yahr PD 
previously. This patient had moderate resting tremor and severe rigidity.!3 
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He also had marked hypokinetic movements. This patient spent 60% of his 
day in the off phase. Following FTT, the patient had a "marked reduction of 
both the number and duration of daily offperiods."13 He spent only 30% of 
his day in the off phase. There were no significant improvements in rigidity 
or tremor. Some gains were made in ann and hand functions up to the 
seventh month but these improvements were not sustained through the 12th 
month. 
Following surgery, these researchers kept the patients' L-dopa dosages at 
pre-operative levels to decrease the risk of improvements being credited to 
changes in medication. 13 The conclusion of this research team was that 
neural grafting has potential as a treatment for PD. However, the results do 
not merit large clinical trials. 
In an ongoing study by Madrazo et al,5 seven patients with PD received 
FTT. Madrazo stated that follow up of these patients is very important. The 
ultimate goal of FTT is to produce long lasting benefits. In a recently 
published article, Madrazo described the status of two FTT PD patients, two 
years post-surgery. 
One patient was a 50 year old male diagnosed with PD nine years 
previously. He had been receiving levadopa therapy at 1,000 mg/day.5 This 
patient suffered from drug induced dystonia and dyskinesia. The second 
patient was a 35 year old female who had PD for five years. 
These patients received FTT two years previously. The progress of the 
patients regarding L-dopa dosages was as follows; patient one went from 
taking 1000 mg/day pre-operative to 500 mg/day at 24 months; patient two 
had been taking 750 mg/day of L-dopa and at six months, her dosage was 
250 mg/day, while at 24 months after surgery, it was 500 mg/day. This 
implied a significant decrease in the patients daily L-dopa requirements.5 
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Time spent in the off phase decreased by 60% in patient one and by 50% 
in patient two over the two year period. s Functionally, patient one had 
"significant amelioration of rigidity, bradykinesia, postural imbalance and 
gait disturbances. liS His tremor was also decreased. This patient was said to 
be leading a normal life, following surgery, including going back to work. 
At two years post FTT, patient two had shown some improvements.s She 
had significant amelioration of only rigidity and bradykinesia, without 
important changes in other signs. She is said to be able to perform 
household tasks and to be of moderate clinical status. 
In conclusion, Madrazo et al S stated that, regardless of the mechanism of 
action, brain transplantation is affecting PD signs to a greater extent than 
previous methods. The authors concluded that the usefulness of tissue 
grafting for neurological diseases cannot be overlooked. 
Additional research by Widner et al 14 reported the technique utilized and 
progress ofFTT in two patients with drug induced Parkinsonism. The major 
difference between this study and the others reviewed was that in the drug 
induced PD, there was no continuation of the disease process. The causative 
agent was no longer present. For this reason, Widner et al may be doing a 
more objective investigation of the viability ofFTT. 
Patient one was a 43 year old male who developed severe Parkinsonism 
following self-injection of the synthesized street drug }"1PTP in 1982.1-l 
L-dopa therapy was causing increasingly severe side effects. This patient 
needed extensive help with eating, dressing and personal hygiene. He had at 
least six off periods each day with as little as 25% of his day in on periods. 
This patient had pronounced hypokinesia, rigidity, and postural 
abnormalities. Patient one was rated a stage IV and occasionally stage V on 
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the Hoehn-Yahr PD scale. During defined "Off' periods he was unable to 
open his eye-lids without help. 
Patient two was a 30 year old female who also developed severe 
Parkinsonism because of an MPTP drug injection.l4 She was becoming 
increasingly intolerant of L-dopa therapy. This patient suffered from 
continuous dyskinesia which rendered her almost completely incapacitated. 
She had five or six off periods each day with 50 to 75% of the day in the on 
phase. This patient required extensive help completing activities of daily 
living. She was rated as a Hoehn-Yahr stage IV. 
Six to eight week old fetal mesencephalic tissue from fetuses was 
injected through a frontal burr hole. There were three placements in the 
putamen and one in the caudate nucleus, bilaterally. At 24 months after 
surgery, patient one had much more independence. 14 He was able to dress 
and feed himself, and go to the bathroom independently. He also made trips 
out of the home. His liOn" time increased to 50-75% of his day and his 
Hoehn-Yahr rating went to a stage three. By 24 months, his rigidity was 
virtually eliminated. His gait became smooth, with a return of natural ann 
swmg. 
Patient two had her L-dopa level reduced by 70% after 18 months.14 At 
22 months after surgery, her dyskinesia was greatly reduced. Also, she had 
"On" phase 50% of the day. She was then rated at a stage II to III on the 
Hoehn-Yahr scale. She was able to feed herself without difficulty. Muscle 
rigidity was ameliorated and she was able to ambulate with spontaneous am1 
swmg. 
The authors concluded that their two patients had made more extensive 
gains than most patients to date. 14 They attributed their success to the fact 
that the the patients received a larger amount of tissue bilaterally, and also 
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that the patients had MPTP induced Parkinsonism as opposed to idiopathic 
PD. This meant that their brain lesions were not progressive and only the 
substantia nigra was affected. However, the researchers admitted that these 
patients improvements were incomplete. Therefore, they felt further 
research was needed before the treatment is adopted clinically. 
CHAPTER 4 
DISCUSSION AND DEBATE OF FTT 
Research is being done all over the world to determine the efficacy of 
neural transplantation. 10 At this point, FTT cannot be disregarded as a useful 
treatment for progressive neurological diseases, namely PD. However, 
neural transplantation for PD is still at an experimental stage and should not 
be used clinically until more research is done. 10,12 This research is likely to 
continue at the same pace as the increasing understanding of the pathology 
of PD.1° Also, with increasing understanding of fetal development, 
researchers will be able to distinguish the best donors.10 In theory, multi-site 
implantations or perhaps a more precise placement of the graft may 
influence further studies. Also a better understanding of graft survival may 
produce a greater therapeutic response. There is the possibility of grafting 
dopaminergic cells in combination with growth factors, to assure the grafts 
integration into the existing tissue. 
To date, much of the improvement seen in patients receiving FIT has 
been antidotal. Subjective measures, whether on the part of the researcher or 
the patient, were often the primary measure of success. A more rigid, 
standard testing battery should be designed and followed closely both pre 
and post operatively by all research teams.6,14 Also, a more systematic 
selection of the: 1) patients to receive the transplants 2) amount ofFT to be 
used, and 3) FTT placement sites would make research more thorough. 13,14 
At present, there are far too many variables in tht:;se studies. It is difficult to 
16 
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credit improvements soley to the procedure.6 It may also be appropriate to 
do the surgery on less involved patients. 8 Then perhaps, more functional 
gains could be made. 
The use of FTT for PD has become a highly debated topic. There are 
those who feel the procedure is unethical and ineffective,7 while others 
contend FTT has potential as a viable treatment for PD .16.17 In the following 
paragraphs, some of the discussions and debates surrounding the use of fetal 
tissue transplants in Parkinsons Disease (PD) is presented. 
According to Rosenfeld et al,7 fetal tissue transplant studies lacked 
vigorous assessment and long-term follow-up . He believed that the clinical 
applications of neurotransplantation for PD was premature. Rosenfeld stated 
that, late in the course of the disease, symptoms cannot be controlled and 
complications arise because of long-term Leva-Dopa therapy. For these 
reasons, other types of therapy for PD need to be explored. According to 
Rosenfeld, there have been eight studies of human fetal grafting in PD, with 
a total of 50 cases. He contended that it would be difficult to interpret the 
results of the studies to date because of the lack of uniformity in assessment 
of responses and the often inadequate follow-up. 
Rosenfeld's 7 theories as to why many of the grafts \vere failing included: 
(a) insufficient quantities of tissue transplanted, (b) the fact that the disease 
process ofPD attacks the newly grafted cells, (c) the possibility that the graft 
site was not optimal, and (d) the initial insult to the tissue may cause 
immediate but short term improvements. Rosenfeld concluded that neural 
transplantation for PD is still in the experimental stages and should not be 
used while many of the major questions remain unans\vered. 
Larry Thompson 15 highlighted recent advances in fetal tissue 
transplantation at the July 1992 4th International Symposium on Neural 
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Transplantation. It was proposed that, currently, research of fetal tissue 
transplants of PD was being done in a haphazard way. Right now, there are 
15 research centers in 11 countries. The consensus was that research would 
be more effective if there were only a few centers to undertake larger clinical 
trials. This would promote more unifonn, systematic assessment of the 
patients and procedures from before surgery through the long-tenn. Over 
all, the consensus at the symposium was one of optimism regarding the 
potential of fetal tissue transplantation as a viable treatment for PD. 
Fahn 16 stated that there has been at least some benefit in humans given 
fetal ventral mesencephalic implants, and in some patients there was 
substantial benefit. Fahn stated that the most impressive results were those 
of Widner et al,14 who studied patients with non-progressive MPTP-induced 
PD. Fahn concluded that this study was important due to the fact that 
patients maintained their improvements, indicating the grafts were surviving 
and growing. 
However, Fahn 16 noted that PD is a progressive disease and the fate of 
the implanted tissue may be the same as that of the original dopamine 
producing cells. This author stated that the most dramatic functional benefit 
of the three studies he critiqued was a statistically significant decrease in off 
time and an increase in on time. Also, the reduction of L-dopa dosage was 
noteworthy. Fahn disputed the notion that the insult to the tissue and 
subsequent healing was the basis for improvement. He contended that 
adrenal medullary grafts caused similar damage with no clear equivalent 
benefit. Fahn concluded that this surgical procedure remained 
investigational but showed optimistic promise for future use. However, 
reports with longer follow-up are essential. 
19 
According to Christopher Goetz et al,17 humans with PD who have 
received fetal nigral transplants to the striatum, have improved clinically_ 
He contended the attraction of surgery is its highly focused targeting, ideally 
suited to a disease like PD in which neurodegeneration is also largely 
circumscribed. 
Sue Fletcher 1 stated that early results of fetal tissue transplantation are 
encouraging. She contended it is unclear, however, if the benefits are the 
result of a placebo effect or another non-specific action of the graft. 
CHAPTERS 
POLITICAL AND ETHICAL ISSUES 
This paper would not be complete without addressing the political and 
ethical issues surrounding FTT. The political influence has been a 
withholding of public funds for research. From 1988 through 1993, there 
was a ban on funding of fetal tissue research in the U.S.18 Consequently, 
fetal tissue research done in the U.S. has been privately funded. 19 The ban 
was originally placed by the Reagan administration to avoid any indication 
that they encouraged abortion. 19 After the moritorium was in effect, a 
Human Fetal Tissue Transplantation Research (HFTTR) Panel was 
appointed to study the matter. 7 Experts in medicine, law and ethics made up 
the 21 member team. In late 1988, the panel "found it acceptable public 
policy to fund the research. "19 However, the recommendation was not 
implemented by the Bush administration, and the moratorium was continued 
indefinitely.20 As recently as February, 1993, the Clinton administration 
lifted the ban on public funding of FTT research. 18 
For FTT experiments to take place, an abortion must have occurred. This 
is the cause of much ethical debate. Anti-abortion proponents contend that 
this research will encourage ambivalent pregnant women to choose 
abortion. 19 If these women think that having an abortion would benefit 
someone else, their decision may be swayed. Perhaps a woman would be 
pressured to conceive in order to supply fetal tissue for a family member 
who has PD.! 
20 
21 
Most supporters of the research believe that "absolute separation of the 
tissue harvesting from the donation procedure is an essential requirement. "7 
Kassirer et al 19 argued that FTT research does not show "support of 
abortion, any more than transplanting organs from murder or accident 
victims constitutes support for murder or accidents. II A woman's decision to 
have an abortion involves a great deal of personal consideration. ls 
According to Kassirer et al,19 it is not the place of the government to 
scrutinize the motives of a woman contemplating abortion. 
Nevertheless, the HFTTR panel developed safeguards to prevent a 
pregnant woman's decision, to have an abortion, from being influenced by 
the possibility of helping another. The guidelines are as follows: 1) A 
woman should not be approached about the issue of FTT until she has made 
her decision to have an abortion; 2) The donor and recipient must not know 
one another; 3) Fetal tissue should not be donated for a specific patient; 
4) There should be no financial incentive either for the woman or for the 
facility.19 It is imperative that the decision to have an abortion and the 
decision to donate tissue are two separate entities. 
There is also the concern about supply and demand. With the continued 
research on fetal implantation in neurological diseases such as PD and 
Alzheimer's, will there be enough tissue to go around? According to 
Fletcher et all, "in the United States, it is estimated that l.6 million 
pregnancies are voluntarily terminated each year, and approximately 78% of 
these occur between the 6th and lIth weeks of pregnancy, which would 
provide adequate supplies of fetal tissue for the present demand. II 
CHAPTER 6 
CLINICAL APPLICATIONS AND CONCLUSIONS 
PD is a progressive, neuromuscular disease that effects the motor 
planning areas of the brain, namely the substantia nigra and basal ganglia. 
PD presents with slowed movement, muscle rigidity, resting tremor and 
postural abnormality. To date there is no cure for PD, however, it is 
controlled primarily through drug therapy.21 
Physical therapy (PT) can be instrumental in helping PD patients improve 
functional ability and combat subsequent deformities. 22 According to 
O'Sullivan et al,2 physical therapy treatment ofPD usually consists of: 
(1) relaxation exercises to reduce muscle tone, (2) range of motion exercises 
to maintain functional mobility, (3) gait training to increase arm swing and 
step length, ( 4) strengthening exercises to prevent muscle atrophy, and 
(5) respiratory exercises to maintain the plyability of chest wall musculature. 
In a study by Formisano et al,23 it was found that, for PD patients, PT 
treatment along with drug therapy was effective in improving functional 
performance. The study compared motor performance test results of 16 test 
patients and 1 7 control patients over a four month period. The test patients 
received physical therapy together with drug therapy, while the control 
groups receive only drug therapy. After four months, the patients receiving 
physical therapy rated higher on the motor performance tests. There was 
also a statistically significant difference in the daily activity scale and 
walking tests. 
22 
23 
FTT could have a great influence on physical therapy treatment of 
patients with PD. Early intervention is the key to the efficacy of physical 
therapy in PD. 23 Those receiving FTT surgery may then enter a 
rehabilitation facility to maximize potential gains. These patients could be 
intensively trained in gait, postural mobility and other functional activities 
immediately following surgery. Also, in many of the studies outlined, 
patients have continued to make gains over as long a period as 24 months. 5,6 
Continued PT has been found to be benificial in helping PD patients 
maintain a high degree of independence as long as possible,23 This suggests 
that these patients would continue to benefit from further physical therapy as 
the FTT grafts integrate into the surrounding tissue. 
There is no literature to date on the physical therapy treatment of PD 
patients receiving FTT. This is perhaps due to the fact that there have been 
only 50 patients in the world who have received FTT.1 However, it is noted 
that in the follow-up of these patients, there has been no mention of 
rehabilitation.5•14 Even with this small number of subjects, individual case 
studies could be done to illustrate the efficacy of PT for these patients. 
With continued research in the area ofFTT surgery, more emphasis could 
be placed on translating the neurological improvement into function. 
Perhaps these patients would make even greater functional gains with the 
incorporation of a comprehensive rehabilitation program following FTT 
surgery. 
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